Limited coverage drugs – iron isomaltoside

iron isomaltoside

100 mg/mL

vial

For the treatment of adult patients with iron deficiency anemia (IDA) who meet the following criteria:

• Patient has a documented diagnosis of IDA confirmed by laboratory testing results (e.g., hemoglobin, ferritin, transferrin saturation)

AND

• Either one of the following:
  • Patient has failed to respond to an adequate trial of at least one oral iron therapy, which requires a minimum of 4 weeks trial period

OR

• Patient is intolerant to at least two oral iron therapies

OR

• Patient has contraindication to oral iron therapy

AND

• Iron isomaltoside must be administered in a setting where appropriate monitoring and management of hypersensitivity reactions can be provided to the patient

Initial: One course of treatment up to a maximum of 2,000 mg per course that must be filled within 28 days

Renewal: One course of treatment at a minimum of 4 weeks after the dispense of the initial dose